Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study

BACKGROUND: Both dabrafenib/trametinib (D/T) and anti-PD-1 monotherapy (PD-1) are approved adjuvant therapies for patients with stage III BRAF V600-mutant melanoma. However, there is still a lack of head-to-head comparative data. We aimed to describe efficacy and toxicity outcomes for these two stan...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Xue, Shaheen, Ahmed, Grieco, Charlotte, d’Arienzo, Paolo D., Mina, Florentia, Czapla, Juliane A., Lawless, Aleigha R., Bongiovanni, Eleonora, Santaniello, Umberto, Zappi, Helena, Dulak, Dominika, Williamson, Andrew, Lee, Rebecca, Gupta, Avinash, Li, Caili, Si, Lu, Ubaldi, Martina, Yamazaki, Naoya, Ogata, Dai, Johnson, Rebecca, Park, Benjamin C., Jung, Seungyeon, Madonna, Gabriele, Hochherz, Juliane, Umeda, Yoshiyasu, Nakamura, Yasuhiro, Gebhardt, Christoffer, Festino, Lucia, Capone, Mariaelena, Ascierto, Paolo Antonio, Johnson, Douglas B., Lo, Serigne N., Long, Georgina V., Menzies, Alexander M., Namikawa, Kenjiro, Mandala, Mario, Guo, Jun, Lorigan, Paul, Najjar, Yana G., Haydon, Andrew, Quaglino, Pietro, Boland, Genevieve M., Sullivan, Ryan J., Furness, Andrew J.S., Plummer, Ruth, Flaherty, Keith T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641479/
https://www.ncbi.nlm.nih.gov/pubmed/37965433
http://dx.doi.org/10.1016/j.eclinm.2023.102290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641479/
https://www.ncbi.nlm.nih.gov/pubmed/37965433
http://dx.doi.org/10.1016/j.eclinm.2023.102290

Ejemplares similares